Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8348550 | 0.86 | SCN8A (0.55) | SCN8ARAB9AALDH1A1LMNAHTT | |
| Hydrochloric Acid SCHEMBL6122751 | 0.84 | SCN8A (0.54) | SCN8ARAB9AALDH1A1LMNA | |
| SCHEMBL22815828 | 0.81 | HDAC1 (0.54) | PPARACHRNA7RAB9AHTTKCNN3 | |
| SCHEMBL2096216 | 0.79 | SLC6A4 (0.49) | CHRNA7ALOX5ALDH1A1 | |
| SCHEMBL255564 | 0.78 | CCR6 (0.50) | PPARACHRNA7ALOX5ALDH1A1LMNA | |
| SCHEMBL23484592 | 0.78 | PPARG (0.48) | PPARACHRNA7ALOX5ALDH1A1 | |
| SCHEMBL23484591 | 0.78 | PPARA (0.50) | PPARA | |
| SCHEMBL2090694 | 0.78 | KIF11 (0.49) | PPARASCN8AALDH1A1 | |
| SCHEMBL3962793 | 0.76 | SCN8A (0.54) | PPARASCN8ARAB9AALDH1A1LMNA | |
| SCHEMBL13123456 | 0.76 | SCN8A (0.50) | PPARASCN8AALDH1A1KCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | GAA 15/4885PPARA 1871/4885SCN8A 3858/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | GAA 15/4885PPARA 1871/4885SCN8A 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.